

Alberta COVID-19 Pharmacy Immunization Program

Introduction

Since March 2020, Alberta Health has been working with the Alberta Pharmacists' Association and other pharmacy stakeholders in developing and launching pharmacy based programs to support Albertans during the pandemic.

Pharmacy teams are accessible, community primary care providers and are in a position to leverage existing relationships to support the pandemic response. Alberta's community pharmacies are an important partner in the success of the COVID-19 Vaccine Response plan.

Alberta receives vaccines, including the COVID-19 vaccine, through the Government of Canada. The federal government determines on a per-capita basis how many vaccines Alberta receives, and tells us when we expect to receive the vaccines. Every province in the country is in the same situation and experiencing similar challenges regarding limited supply of the vaccines from the federal government at this time. As the vaccine supply and timing is variable and can be changed on short notice, changes to the Program may be made to reflect this accordingly.

Program Purpose

The purpose of the Alberta COVID-19 Pharmacy Immunization Program (ACPIP) is to provide Albertans access to vaccine in a timely manner as vaccine supply increases (access).

In the first stage of the ACP/IP, due to limited vaccine quantities and strict storage and handling requirements for the Pfizer-BioNTech vaccine, 102 pharmacies in Edmonton, Red Deer and Calgary were invited to participate as a proof of concept approach until there is adequate COVID-19 vaccine supply to expand distribution. The first stage was initiated March 4, 2021.

The second stage began March 15, 2021 and introduced an additional 157 pharmacies located throughout the province. By the week of April 5, 2021, over 1,300 were enabled to administer COVID-19 vaccine to Albertans.

Early-participating pharmacies were invited by Alberta Health to participate based on data from the 2020-2021 Influenza Immunization Program which demonstrated that these pharmacies have high daily immunization capacities, access to a large number of Albertans who were eligible to receive vaccine in the early phases of the COVID-19 immunization program, and have consistently entered information within required timelines via Alberta Blue Cross claims. In addition to using influenza vaccine administration data, specific pharmacies and the type vaccine distributed was influenced by the following factors:

- Limited and inconsistent vaccine supply provided by the federal government;
- Vaccine stability while in transport;
- Shelf-life of mRNA vaccines once in the thawing or thawed state; and
- Pharmacy wholesale distributor capacity to ship vaccine supply to pharmacies in different areas.

Eligibility for Immunization

The Alberta government is implementing a phased approach to target key populations in the earliest phases of the COVID-19 Immunization Program. The precise timeframes for each phase depend on the availability of the vaccine. To determine who is included in each phase of the plan, Alberta Health considered the recommendations from the National Advisory Committee on Immunization (NACI) and the experts who sit on Alberta's Advisory Committee on Immunization. Please visit <https://www.alberta.ca/covid19-vaccine.aspx> for more information about Alberta's COVID-19 immunization program and the planned phases and associated eligibility criteria.

Key groups in Phase 1 of the COVID-19 Immunization Program were chosen in an effort to reduce severe illness and death and to protect individuals who are exposed to Albertans experiencing the highest burden of COVID-19 disease. This phase of the program started in December and will continue until all Albertans eligible under this phase are immunized.

Phase 1B included all seniors 75 years of age and older (individuals born in 1946 or earlier), as well as First Nation, Métis and Inuit (FNMI) persons 65 years of age and over living on a First Nation reserve or Metis Settlement.

Community pharmacies began immunizing seniors 75 years of age and older in the community as part of Phase 1B (individuals born in 1946 or earlier) on March 4, 2021. Phase 2A of the program launched on March 15, 2021. Albertans eligible under phase 2A include all seniors born 1947 to 1956 (turning 65 to 74), no matter where they live, FNMI persons born 1971 or earlier (turning 50+) not matter where they live, and staff and residents of licensed supporting living (seniors) not included in Phase 1.

On March 30, 2021, Phase 2B was launched in community pharmacies. Phase 2B eligibility includes Albertans born 2005 to 1957 (16 to 64) with eligible high-risk underlying health conditions. Eligible health conditions can be found [here](#). Phase 2B appointment bookings will be completed using a phased approach based on birth year. As of April 6, participating pharmacies in with sufficient vaccine supply are booking appointments for Albertans with eligible high-risk underlying conditions born in 1957-1973. Appointments for more Phase 2B eligible Albertans will be opened up in April, and Pharmacies will be kept aware of the eligibility groups as they evolve.

Alberta Health Services (AHS) in their role as an immunization partner is also providing vaccine to Albertans eligible based on Phase 1, 2A and 2B.

The AstraZeneca vaccine became available through community pharmacies during the week of April 5. A portion of Phase 2D individuals are eligible to receive this vaccine: Albertans age 55 to 64 without high-risk underlying health.

Across Canada, administration of the AstraZeneca vaccine is being paused for those under the age of 55 while investigation continues regarding Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT). Additional information can be found at <https://www.ab.bluecross.ca/providers/pharmacy-covid-19-immunization.php>

The AstraZeneca vaccine remains a good choice for Albertans age 55 to 64 based on their age-related risk of severe outcomes from COVID-19. These Albertans would otherwise have to wait several months to access a vaccine for their protection.

ACPIP Requirements

This is a **voluntary** program for Alberta pharmacists working in community pharmacy locations.

This is a **voluntary** program for Albertans, immunization for COVID-19 is NOT mandatory. However, immunization is **strongly encouraged** for all eligible Albertans.

The Alberta government has standardized practices for all immunization providers, regardless of whether a vaccine is provincially funded or privately purchased. As outlined in the *Immunization Regulation*, as of December 17, 2018:

- Health practitioners shall ensure that adverse events following immunization (AEFI) are reported to Alberta Health Services within 3 days of becoming aware.
- The Regulation also sets out requirements for the storage, handling and transportation of vaccines

As of January 1, 2021, the *Immunization Regulation* requires health practitioners to ensure a report respecting immunizations and assessments is electronically submitted to Alberta Health within 7 days. Alberta Health will be facilitating a way for all pharmacies to meet with requirements under the *Immunization Regulation* to provide pharmacies with time to become compliant via real time integration.

For the requirements of this program, Alberta Blue Cross billing claims for the ACP/IP are required to be billed on the day of service provided by the pharmacy.

Pharmacies will be reimbursed \$25 for each COVID-19 vaccine administered.

NOTE: Pharmacies that utilize other regulated health care providers (e.g. Registered Nurse, Licensed Practical Nurse, etc.) to support COVID-19 administration practices within the pharmacy are **not** able to bill the administration of the vaccine. The pharmacy services framework is designed to support the clinical practice of pharmacists.

Pharmacists have a professional responsibility to monitor Alberta Health COVID-19 daily updates and bulletins for changes to this program and/or the overall immunization strategy.

Pharmacists are required to **pre-book** all COVID-19 immunization appointments in order to pre-screen eligible Albertans and to manage the limited vaccine supply. Orders for COVID-19 vaccine are based upon confirmed booked appointments, extra inventory will NOT be provided, unless otherwise communicated.

Albertans who contacted a community pharmacy before March 10 and received confirmed appointment bookings for the first and second dose will have their second dose appointment honoured. The second dose must be provided at 42 days, and not earlier.

The NACI and Public Health authorities are advising, based on the most current evidence available, that the interval between doses should be extended up to four months (i.e. 16 weeks).

Starting March 10, only appointments for the first vaccine dose should be booked. The pharmacy will contact the Albertan to book the second dose at a later date after further direction is provided by Alberta Health.

Albertans should be encouraged to stay with the same pharmacy for both immunizations to ensure proper timing, follow-up and documentation.

Pharmacies are encouraged to maintain a waitlist, in the event that a pre-booked appointment is unable to attend the pharmacy for immunization, this will help to reduce wastage of vaccine doses.

COVID-19 mRNA Vaccines

COVID-19 mRNA vaccines are a new class of vaccine products and pharmacists and pharmacy technicians must ensure that they have read and familiarized themselves with the technical, clinical and operational requirements of handling this vaccine. Particular attention is required for the Pfizer-BioNTech vaccine and the instructions for reconstitution and drawing up of doses with low-dead space (LDS) needles and syringes which will ensure maximization of available doses from each vial. LDS needles/syringes are not required for the Moderna vaccine.

Training resources which every immunizer is required to review are provided at the end of this program document. Additional training resources may be provided by each individual manufacturer, and their website should be reviewed for content for Health Professionals.

Pharmacists are reminded, as always, to practice within their competencies and abilities. The Alberta College of Pharmacy has reviewed the program requirements of the ACPIP.

AstraZeneca is not a mRNA vaccine.

Inbound Logistics

Vaccine and distribution of injection supplies and diluent for pharmacies receiving the Pfizer-BioNTech will be supplied to participants thru McKesson Canada. Distribution of the Moderna vaccine will be thru FedEx and/or McKesson and associated injection supplies will be supplied by McKesson. Due to strict storage and handling requirements for all mRNA vaccines, only McKesson Canada (Pfizer-BioNTech and Moderna) and FedEx (Moderna drop-shipping) have been invited to distribute the vaccines. Distribution of AstraZeneca and supplies needed for its administration will be through a pharmacy's usual and customary wholesale distributor – this same distribution channel is anticipated for other fridge stable vaccines (ie. Janssen) as they become available in Alberta, an update to this document will be made if this direction changes.

Pharmacies administering the Pfizer-BioNTech vaccine will receive a vaccine shipment twice weekly from McKesson after the pharmacy indicates their weekly supply requests with McKesson. Pharmacies administering the Moderna vaccine will automatically receive a pre-established fixed quantity of vaccine from FedEx or McKesson (when supply is available). AstraZeneca pharmacies will be able to order vaccine through their usual and customary wholesale distributor.

COVID-19 mRNA vaccines will be shipped to participants from McKesson or FedEx in a thawed or thawing state and must be refrigerated in a laboratory-grade vaccine fridge IMMEDIATELY upon arrival without delay. Participants should make accommodations within their workflow/operations to ensure the receiving process for vaccine is done expediently to mitigate any risk of cold chain break.

More specific information on mRNA vaccine storage and handling requirements can be found below. Additional information can be found within **Pharmacy Benefact 942** and **943**.

- [Alberta Vaccine Storage and Handling for COVID-19 Vaccine](#)

- Drug information on approved vaccines in Canada
 - [Pfizer BioNTech](#) received approval on Dec. 9, 2020.
 - [Moderna](#) received approval on Dec. 23, 2020
 - [AstraZenca](#) received approval on Feb. 26, 2021
 - [Janssen](#) received approval on Mar 5, 2021

Client Booking for Immunization Appointments

Participating pharmacies are encouraged to contact eligible individuals from their local client records for each pharmacy site.

Solicitation of potential clients using any other means (i.e. database lookups from a central location) is not supported and may not be in alignment with the Standards of Practice for Pharmacists and Pharmacy Technicians.

Any eligible Albertans who are not clients of the pharmacy are also to be scheduled for an immunization appointment upon contacting the pharmacy site. Participating pharmacy sites will be publicly posted for Albertans to contact in order to book appointments for immunization, and public communications to Albertans will encourage eligible Albertans to reach out to their closest participating pharmacy.

Pharmacies must ensure that all immunizations are scheduled by appointment in order to manage vaccine inventory strictly and to prevent high-risk individuals from unnecessary exposure or security risks due to large crowds or lineups.

Appointments should be booked in multiples of clients to coincide with the number of doses of vaccine per vial which can be safely immunized.

Dependent on the type and size of needle and syringe used, it is possible to attain extra doses from the vial, however this is not consistent between all combinations of needle and syringe in the community setting. The number of doses should be maximized by program participants by using low-dead space (LDS) syringes for the Pfizer BioNTech vaccine and utilizing proper technique for withdrawing doses from each vial.

Regardless of the skill of the pharmacist, a maximum of six doses (Pfizer-BioNTech) and 10 doses (Moderna/AstraZeneca) should be withdrawn from their applicable multi-dose vials. This maximum amount is dictated by Health Canada and the vaccine manufacturer.

In order to be immunized by a pharmacist, the presenting client **MUST** be asymptomatic. This should be confirmed at the time of booking as well as immediately prior to each immunization appointment in the two dose series.

Screening for eligibility (absence of symptoms or history of previous positive testing in the last 14 days) will be the responsibility of the pharmacist and will be guided by an assessment tool which can be found on the AHS website at;

<https://myhealth.alberta.ca/Journey/COVID-19/Pages/COVID-Self-Assessment.aspx>

Pharmacists must check NETCARE for client history of previous testing in particular to determine if client has had a positive result in the last 14 days. If there is a positive test result in the last 14 days, then the client should be referred to an AHS Health Link for further information by calling 811.

If a client screens as being symptomatic, or at high-risk for previous exposure to COVID-19, or works or lives at a site with a declared outbreak; as per the online assessment tool protocol, clients **MUST** be advised to self-isolate and be referred to an AHS Assessment Center for testing by calling 811.

If a screening indicating the client is symptomatic or high-risk for previous exposure occurs in the pharmacy, then the pharmacy is to follow the hierarchy of controls, specifically with respect to environmental controls and cleaning. (see following section)

Pharmacists must check the immunization module in NETCARE for previous administration of COVID-19 vaccine and type. Pharmacists must ensure that any individual previously immunized with a COVID-19 vaccine complete the required series with the same vaccine type previously used. COVID-19 vaccines are NOT interchangeable and there is insufficient clinical evidence to determine the long term ramifications of switching products.

A Client Consent and Checklist for ACPIP has been developed to assist pharmacists' in ensuring all the necessary steps are followed for each client requesting immunization. This can be found at <https://www.ab.bluecross.ca/providers/pharmacy-covid-19-immunization.php>

Infection Prevention and Control

The Alberta College of Pharmacy has developed guidelines that contribute to a hierarchy of controls, which must be in place during a public health response.

AHS standard operating procedure for immunization recommends PPE consisting of mask, and face shield or goggles. Hand hygiene practices must be strictly enforced and used at all times.

Gloves are not required, but use is encouraged when possible. If gloves are used, they must be changed after each client with proper hand hygiene before putting gloves on and after removal of gloves.

N95 respirators are not required as immunization is not an aerosol generating medical procedure (AGMP).

Gowns are not required, but may be used at the discretion of the pharmacist.

Pharmacies can source and acquire appropriate PPE from a supplier(s) of their choice. The cost of PPE is covered through program fees.

- General Applicable Guidance on infection prevention and control
 - o <https://abpharmacy.ca/COVID-19-guidance-pharmacists-and-pharmacy-technicians>
- Personal Protective Equipment Approach
 - o <https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-COVID-19-ppe-faq.pdf>

- Risk Mitigation in Workplaces
 - <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/risk-informed-decision-making-workplaces->
- Environmental Controls
 - <https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-COVID-19-community-physicians-environmental-cleaning.pdf>
 - <https://www.albertahealthservices.ca/assets/healthinfo/ipc/if-hp-ipc-bpg-ready-to-use-wipes-info.pdf>

Immunization with COVID-19 Vaccine

Immunization of eligible Albertans must **ONLY** occur on-site in the participating pharmacy. Off-site or ambulatory provisions are **NOT** supported at this time.

McKesson Canada will provide the required diluent (i.e. for Pfizer BioNTech), syringes and needles and other ancillary supplies (except PPE, unless sourced separately by the pharmacy from McKesson) for the administration of the mRNA vaccines as an initial distribution with the first order. McKesson will provide ancillary supplies to match mRNA vaccines, ordering may be required in the future, please watch for communications from McKesson regarding ordering of vaccines and ancillary supplies as the program matures.

A client consent script as part of the ACPIP Client Consent and Checklist will guide pharmacists to obtain informed consent for immunization with COVID-19 vaccine.

Prior to immunization, the pharmacist must ensure that all necessary supplies and ancillary items are readily available in order to avoid wastage of any doses.

Best practice include these mandatory requirements

- Low dead-space 1cc syringe for the Pfizer BioNTech vaccine
- 3mL needle for Pfizer BioNTech vaccine
- 3cc syringe for the Moderna/AstraZeneca vaccines
- Client appropriate needle to withdraw dose from vial and administer to client
- Alcohol swabs
- Sharps Container
- Hand sanitizer
- PPE
- Workspace Infection Prevention and Control materials
- Active surveillance information and QR code (see Reporting Requirements).

- Up to date emergency training, supplies, and polices to respond to an emergency event, especially for anaphylaxis.

Guidance from the manufacturer instructions on preparing the vaccine, precautions and contraindications for administration can be found in the product monograph for each COVID-19 vaccine.

Once the vial of vaccine has been punctured, it is stable for short-term storage at as per the product monographs. Pharmacists **MUST** be aware of these timelines as they are variable between different products.

ALL doses **MUST** be administered from a vial within this time, otherwise any remaining doses are spoiled and **CANNOT** be used.

Prefilling of syringes is **NOT** supported.

DUE TO VACCINE SUPPLY LIMITATIONS, PARTICIPANTS MUST ENSURE THAT ANY POTENTIAL FOR WASTAGE OR SPOILED DOSES IS MITIGATED TO THE BEST OF THEIR ABILITIES.

Recommendations for possible mitigation strategies include, but are not limited to;

- Overbooking appointments by up to 5% to allow for potential “no-shows” or individuals who may not pass screening on the day of immunization. Clients should be notified that they may not receive vaccine if all booked appointments show up that day.
- Create a “standby list” that includes eligible Albertans who can be reached on short notice, be quickly pre-screened, and are able to come in for immunization in the event of cancellations or “no-show” appointments.
- Doses remaining at the end of the day can be used according to Alberta Health guidance for the next most appropriate individuals. Vaccine Wastage Guidance can be found at <https://www.ab.bluecross.ca/providers/pharmacy-covid-19-immunization.php>

Reporting Requirements

Participants are required to, **every day**;

1. Submit ALL claims for the vaccine that was administered.

2. Submit ALL Adverse Events Following Immunization to Alberta Health Services

- <https://www.albertahealthservices.ca/info/Page16187.aspx>

Should an adverse event related to immunization be observed or reported to the pharmacist at any time post-immunization, it is paramount that these events be reported to the Alberta Health Services AEFI team through <https://www.albertahealthservices.ca/info/Page16187.aspx> or at [1-855-444-2324 \(1-855-444-CDCI\)](tel:1-855-444-2324) if unable to complete the online form.

The pharmacist must be familiar with the adverse events that are reportable including the adverse events of special interest that is particular to the COVID-19 vaccine.

The Alberta Health [Active Surveillance and Reporting of Adverse Events following COVID-19 Immunization](#) Policy outlines the reportable AEFIs.

3. Alberta Vaccine Inventory (AVI) Reporting Process

Pharmacies will be required to access the AVI Portal on a daily basis to complete required reporting. Pharmacies that have not already done so are required to complete the enrolment for access to the AVI system as soon as possible by completing the form found at: <https://forms.gle/F6rKtRgNT7Lkq5Dq8>.

You can enroll up to four on-site users per pharmacy site who will be responsible for submitting daily records. Please complete all fields on all pages and submit the information to be uploaded to AVI. All locations holding any quantity of COVID-19 vaccine must complete a daily physical count and reconciliation of their on-hand inventory by 9 pm. The on-hand quantities reported in AVI are used to manage inventory in the province and accuracy is essential to managing the COVID-19 vaccine program.

Training videos are available on the AVI home page (<https://vimsavi.alberta.ca/prod/>). For questions on the AVI process please contact the AVI Help Desk at 1-844-213-3600.

Vaccine allocations will be reconciled by Alberta Health against this data for each participant site on a daily basis and allocation amounts may be reduced if the requested amounts cannot be corroborated by the data.

4. COVID Vaccine Appointment Reporting Portal

Pharmacies participating in the Alberta COVID-19 Pharmacy Immunization Program (ACPIP) are required to report information about their booked COVID-19 vaccine appointments to Alberta Health on a daily basis through the COVID Vaccine Appointment Reporting Portal.

The email address provided for your pharmacy on the ACPIP enrollment form will be used for all communications regarding the online reporting portal. Pharmacies will start to receive the following

emails:

- An initial registration email from no-reply-COVID-vaccine-appt-reporting@gov.ab.ca inviting your pharmacy to the portal. This email will include a **unique access code** that your pharmacy will use daily to report your booking activities.
- Each morning a direct link to the portal will be sent out. You will use your unique access code to enter the portal and submit your site's daily report.
 - The link in the daily email will only be active for the day that it is sent (24 hours). A new link will be provided the next morning.
- A reminder email will be sent in the evening if you have not accessed the portal that day.
- A reminder email will be sent to participating pharmacies that have not accessed the portal two days in a row.

Within the portal you will be asked to provide:

- the 'next available appointment date';
- the number of patients on your waitlist (if applicable);
- the sustainable maximum number of vaccinations per week your pharmacy can administer (this value represents the number of vaccinations that your pharmacy can administer consistently, week-to-week, assuming your pharmacy is receiving consistent vaccine supply); and
- **information about your bookings for each day including:**
 - the number of bookings on each day;
 - which vaccine product will be administered (if known);
 - whether appointments are for a first or second dose; and
 - eligibility phase of patients (i.e. 1B, 2A, 2B, etc.).

Once you have completed the first report, the information you provide will remain populated in the reporting tool for daily updating. Each day pharmacies will need to make updates to their report. Even if there are no changes, or no appointments are available or booked, each pharmacy is expected to access the portal and submit their report daily. Pharmacies will only be required to update their appointment information on their regular days of operation.

If you have questions regarding accessing the portal or need IT support, please contact the Alberta eHSS team by email or phone. Pharmacies can call between 9 a.m. and 9 p.m. on weekdays and 9 a.m. and 5 p.m. on weekends and holidays.

- Phone: 1-844-956-4141
- Email: Support.COVID.Vaccine.Appt.Reporting@cqi.com

More detailed information and instructions for use of the reporting portal and FAQs can be found on the Alberta Blue Cross website at <https://www.ab.bluecross.ca/providers/pharmacy-covid-19-immunization.php>.

Patient Based National Survey

In addition, there is a client based national survey study to conduct active safety surveillance on the COVID-19 vaccines. The study is optional, and usually takes less than one minute to complete online. The study has received ethics and privacy approvals from all the appropriate groups.

The initiative would include three email surveys in total which will be sent to clients:

- one on day 8 after dose 1,
- the second on day 8 of dose 2, and
- the third six months after vaccine to help gather more information on the COVID-19 vaccine.

The surveys were developed by CANVAS, the Public Health Agency of Canada (PHAC) and the F/P/T Vaccine Vigilance Working Group (VWVG) and will be utilized by other participating provinces and territories. This information will be collected and provided to Alberta Health surveillance.

Enrollment should occur at the time of immunization with the QR code available at <https://www.ab.bluecross.ca/providers/pharmacy-covid-19-immunization.php> or by providing the link <https://canvas-covid.ca/>

Additional Recommended Resources

Information regarding the development of these vaccines and their safety can be found below.

- Q&A Document from Alberta Health
 - [COVID-19 Vaccine – Questions and answers for health-care practitioners](#)
- Health Canada
 - [What you need to know about the COVID-19 vaccine for Canada](#)
 - [COVID-19: How vaccines are developed](#)
 - [Vaccine safety, concerns and possible side effects](#)

For immunization providers:

- The Alberta COVID-19 Immunization Policy will be forthcoming.

- [Alberta Immunization Policy](#)
- [Guidance for the delivery of COVID-19 immunization services](#)
- [Direction from the Chief Medical Officer of Health to seek further assistance from regulated health practitioners with COVID-19 immunization.](#)

Manufacturer resources:

- COVID-19 vaccine product monographs;
 - [Pfizer BioNTech COVID-19 vaccine](#)
 - [Moderna COVID-19 vaccine](#)
 - [AstraZeneca COVID-19 vaccine](#)
 - [Janssen COVID-19 vaccine](#)
- Handling of the Pfizer BioNTech vaccine, including the dry-ice training- webinars: <https://www.cvdvaccine.ca/>
- Handling of Moderna vaccine: <https://www.modernacovid19global.com/ca>
- Training on the Low Dose Syringes: Training: the National Collaborating Centre for Infectious Diseases (NCCID) hosted a webinar on Feb 10th for health care providers who are administering COVID-19 vaccines.
 - This webinar has been recorded and available on the NCCID website
 - [Presentation on Allergies and Anaphylaxis following administration of COVID-19 vaccines with live Q&A Live Q&A panel on Low Dead Volume Syringes](#)

Alberta Health Resources:

- [Alberta's COVID-19 Immunization Policy](#)
- [COVID-19 vaccine biological pages:](#)
 - [COVID-19 Vaccine \(mRNA\) – Moderna frozen vaccine](#)
- [Alberta Vaccine Storage and Handling for COVID-19 Vaccine;](#)
- [Active Surveillance and Reporting of Adverse Events following COVID-19 Immunization \(AEFI\) Policy;](#)
- [COVID-19 Vaccine – Questions and answers for health-care practitioners;](#)
- [COVID-19 immunization: Guidance during the COVID-19 pandemic;](#)
- [Product Problem form](#)

Optional:

Alberta Health Services:

- [COVID-19 Vaccine Fact Sheet](#)

National resources:

- [The National Advisory Committee on Immunization \(NACI\) Recommendations on the use of COVID-19 vaccine](#)
- [Webinars on COVID-19 vaccines](#)
- [Planning guidance for immunization clinics for COVID-19 vaccines](#)